Physician profile
Scott H Mackenzie
NPI 1568501997
$12,883.34
in general payments reported to CMS, 2019-2025
37 companies · $2,696 in 2025
The $2,696 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,280 · 2020: $764 · 2021: $1,495 · 2022: $2,402 · 2023: $2,085 · 2024: $2,162 · 2025: $2,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,861 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62.50 · Education: $19.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,861.06 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62.50 |
| Education | $19.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,359.19 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,941.61 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $1,061.64 | 2019-2025 | |
| Janssen Biotech, INC. | $777.74 | 2019-2025 | Stelara, Tremfya, Simponi |
| Genzyme Corporation | $768.73 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $463.76 | 2022-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $440.52 | 2021-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $355.58 | 2019-2025 | Xifaxan |
| Pfizer INC. | $347.98 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $302.03 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $238.59 | 2023-2025 | Zenpep |
| Allergan, INC. | $221.65 | 2020 | |
| Lilly USA, LLC | $212.07 | 2025 | Omvoh |
| Celgene Corporation | $174.82 | 2021-2024 | Zeposia |
| Celltrion USA INC. | $135.05 | 2024-2025 | Vegzelma, Zymfentra |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $122.13 | 2019 | |
| Intuitive Surgical, INC. | $100.00 | 2022 | |
| Madrigal Pharmaceuticals | $96.57 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $85.23 | 2019-2025 | Sucraid |
| Shionogi INC | $81.27 | 2019 | |
| Ironwood Pharmaceuticals, INC | $71.21 | 2019-2020 | |
| Ardelyx, INC. | $62.11 | 2024-2025 | Ibsrela |
| Daiichi Sankyo INC. | $59.40 | 2022-2024 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $57.57 | 2024-2025 | Iqirvo |
| Organon LLC | $57.01 | 2025 | Hadlima, Renflexis |
| Phathom Pharmaceuticals, INC. | $48.28 | 2024 | Voquezna |
| Ethicon US, LLC | $35.48 | 2019-2023 | Linx Reflux Management System |
| Steris Corporation | $26.25 | 2023 | |
| Biocon Biologics INC | $25.06 | 2025 | Yesintek |
| Novo Nordisk INC | $24.06 | 2024 | Wegovy |
| Laborie Medical Technologies Corp. | $21.03 | 2024 | |
| Fresenius Kabi USA, LLC | $20.21 | 2023 | Idacio |
| Braintree Laboratories, INC. | $20.14 | 2020 | |
| Ferring Pharmaceuticals INC. | $18.84 | 2021 | |
| Endo Pharmaceuticals INC. | $17.58 | 2019 | |
| Merck Sharp & Dohme LLC | $17.27 | 2019 | |
| Conmed Corporation | $15.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Mackenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.